Evidence map›Paper›PMID 41074076›Full record

ArticleBMC medicine2025

VEGFA sex-specific signature is associated to long COVID symptom persistence.

Xavier Farré, Natalia Blay, Susana Iraola-Guzmán, Francisco Fernández-Jiménez, Sayoa Alzate-Piñol, Laia Llucià-Carol, Ana Espinosa, Gemma Castaño-Vinyals, Carlota Dobaño, Gemma Moncunill and 6 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xavier FarréGenomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain.
Natalia BlayGenomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain.
Susana Iraola-GuzmánGenomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain.
Francisco Fernández-JiménezGenomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain.
Sayoa Alzate-PiñolStroke Pharmacogenomics and Genetics Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
Laia Llucià-CarolStroke Pharmacogenomics and Genetics Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
Ana EspinosaISGlobal, Barcelona, Spain.
Gemma Castaño-VinyalsISGlobal, Barcelona, Spain.
Carlota DobañoISGlobal, Barcelona, Spain.
Gemma MoncunillISGlobal, Barcelona, Spain.
Marianna KarachaliouISGlobal, Barcelona, Spain.
Judith Garcia-AymerichISGlobal, Barcelona, Spain.
Manolis KogevinasISGlobal, Barcelona, Spain.
Carles BarcelóFaculty of Health Sciences at Manresa, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain.
Israel CadenasStroke Pharmacogenomics and Genetics Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
Rafael de CidGenomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain. rdecid@igtp.cat.

Funding

Fundació la Marató de TV3 167/C/2021HORIZON EUROPE Framework Programme GA:101046314'la Caixa' Foundation SR20-01024Ministerio de Ciencia e Innovación CEX2018-000806-SMinisterio de Ciencia e Innovación TED2021-130626B-I00Ministerio de Sanidad, Política Social e Igualdad PI18/01512Ministerio de Sanidad, Política Social e Igualdad PI20/01267
6 · The paper itself

Abstract

backgroundLong COVID involves persistent symptoms after COVID-19 recovery, affecting multiple organ systems for months or years. Risk factors include female sex, prior chronic conditions, severe SARS-CoV-2 infection, reinfections, and lack of vaccination. As a major public health concern, ongoing research continues to investigate its causes, mechanisms, and long-term effects.

methodsProteomic expression analysis of 171 individuals, in two time points, with confirmed SARS-CoV-2 infection, including 133 long COVID patients from the deeply characterized COVICAT cohort, assessed 1395 protein biomarkers using Olink® technology. Statistical analyses with linear mixed models examined protein expression changes, long COVID status, and sex-specific differences. Functional analysis included gene set enrichment analysis and protein-protein interaction networks.

resultsFindings revealed VEGFA overexpression in long COVID patients (effect size 0.322, SE = 0.098, p = 0.0013), along with sex-specific expression patterns and the influence of sex-hormonal status in females, with significant overexpression of circulating VEGFA levels specifically in postmenopausal women (Mann-Whitney U test p value = 8.55 × 10

conclusionsUsing high-throughput proteomic profiling in a population-based cohort, we observed that vascular dysfunction, particularly involving VEGFA, is a key feature of long COVID, especially in milder cases, with significant overexpression of VEGFA in postmenopausal women. Sex-specific proteomic patterns suggest distinct recovery mechanisms, highlighting the need to consider sex, vascular health, and disease severity in the pathogenesis and management of long COVID.

Indexed as

COVID-19Vascular Endothelial Growth Factor AAdultAgedBiomarkersFemaleHumansMaleMiddle AgedProteomicsSARS-CoV-2Sex FactorsBiomarkersVascular Endothelial Growth Factor AVEGFA protein, humanCOVID-19Long COVIDMolecular epidemiologyProteomeSex differences

Identifiers

PMID41074076
PMCPMC12512802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.